{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:28:20Z","timestamp":1792013300433,"version":"4.4.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"DOI":"10.1007\/s11894-025-01030-1","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T02:15:59Z","timestamp":1768356959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Fecal Microbiota Transplantation in 2025: Two Steps Forward, One Step Back"],"prefix":"10.1007","volume":"28","author":[{"given":"Charles B.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey A.","family":"Bader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl L.","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"issue":"5","key":"1030_CR1","first-page":"854","volume":"44","author":"B Eiseman","year":"1958","unstructured":"Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958;44(5):854\u20139.","journal-title":"Surgery"},{"issue":"4","key":"1030_CR2","first-page":"178","volume":"47","author":"TA Bowden","year":"1981","unstructured":"Bowden TA, Mansberger AR, Lykins LE. Pseudomembraneous enterocolitis: mechanism for restoring floral homeostasis. Am Surg. 1981;47(4):178\u201383.","journal-title":"Am Surg"},{"issue":"2","key":"1030_CR3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3109\/00365548409087145","volume":"16","author":"A Schwan","year":"1984","unstructured":"Schwan A, Sj\u00f6lin S, Trottestam U, Aronsson B. Relapsing clostridium difficile enterocolitis cured by rectal infusion of normal faeces. Scand J Infect Dis. 1984;16(2):211\u20135.","journal-title":"Scand J Infect Dis"},{"issue":"7","key":"1030_CR4","first-page":"1027","volume":"118","author":"S Lund-T\u00f8nnesen","year":"1998","unstructured":"Lund-T\u00f8nnesen S, Berstad A, Schreiner A, Midtvedt T. Clostridium difficile-associated diarrhea treated with homologous feces. Tidsskr Nor Laegeforen. 1998;118(7):1027\u201330.","journal-title":"Tidsskr Nor Laegeforen"},{"issue":"11","key":"1030_CR5","first-page":"3283","volume":"95","author":"SE Persky","year":"2000","unstructured":"Persky SE, Brandt LJ. Treatment of recurrent clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope. Am J Gastroenterol. 2000;95(11):3283\u20135.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"1030_CR6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.anaerobe.2009.09.007","volume":"15","author":"JS Bakken","year":"2009","unstructured":"Bakken JS. Fecal bacteriotherapy for recurrent clostridium difficile infection. Anaerobe. 2009;15(6):285\u20139.","journal-title":"Anaerobe"},{"issue":"12","key":"1030_CR7","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.cgh.2011.08.014","volume":"9","author":"JS Bakken","year":"2011","unstructured":"Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2011;9(12):1044\u20139.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"1030_CR8","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1093\/cid\/cir632","volume":"53","author":"E Gough","year":"2011","unstructured":"Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent clostridium difficile infection. Clin Infect Dis. 2011;53(10):994\u20131002.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1030_CR9","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/ajg.2013.59","volume":"108","author":"Z Kassam","year":"2013","unstructured":"Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol. 2013;108(4):500\u20138.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"1030_CR10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1056\/NEJMoa1205037","volume":"368","author":"E Van Nood","year":"2013","unstructured":"Van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, De Vos WM, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407\u201315.","journal-title":"N Engl J Med"},{"key":"1030_CR11","unstructured":"Guidance for Industry: Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation To Treat Clostridium difficle Infection Not Responsive to Standard Therapies; Availability. Department of Health and Human Services Food and Drug Administration [Docket No. FDA-2013-D-0811]. Available at https:\/\/www.federalregister.gov\/documents\/2013\/07\/18\/2013-17223\/guidance-for-industry-enforcement-policy-regarding-investigational-new-drug-requirements-for-use-of. Accessed November 2, 2025."},{"key":"1030_CR12","unstructured":"Chen J. Fecal Microbiota Transplantation: An introduction to FMT, its history, and therapeutic potential. 2021; Available at http:\/\/openbiome.org. Accessed 15 May 2025."},{"issue":"9","key":"1030_CR13","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/apt.13144","volume":"41","author":"G Cammarota","year":"2015","unstructured":"Cammarota G, Masucci L, Ianiro G, Bibb\u00f2 S, Dinoi G, Costamagna G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015;41(9):835\u201343.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"1030_CR14","doi-asserted-by":"publisher","first-page":"609","DOI":"10.7326\/M16-0271","volume":"165","author":"CR Kelly","year":"2016","unstructured":"Kelly CR, Khoruts A, Staley C, Sadowsky MJ, Abd M, Alani M, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent clostridium difficile infection: A randomized trial. Ann Intern Med. 2016;165(9):609\u201316.","journal-title":"Ann Intern Med"},{"issue":"5","key":"1030_CR15","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1053\/j.gastro.2018.12.019","volume":"156","author":"CL Hvas","year":"2019","unstructured":"Hvas CL, Dahl J\u00f8rgensen SM, J\u00f8rgensen SP, Storgaard M, Lemming L, Hansen MM, et al. Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent Clostridium difficile infection. Gastroenterology. 2019;156(5):1324-1332.e3.","journal-title":"Gastroenterology"},{"issue":"4","key":"1030_CR16","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1053\/j.gastro.2017.01.028","volume":"152","author":"CR Kelly","year":"2017","unstructured":"Kelly CR, Kim AM, Laine L, Wu GD. The aga\u2019s fecal microbiota transplantation National registry: an important step toward understanding risks and benefits of microbiota therapeutics. Gastroenterology. 2017;152(4):681\u20134.","journal-title":"Gastroenterology"},{"issue":"1","key":"1030_CR17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1053\/j.gastro.2020.09.038","volume":"160","author":"CR Kelly","year":"2021","unstructured":"Kelly CR, Yen EF, Grinspan AM, Kahn SA, Atreja A, Lewis JD, et al. Fecal microbiota transplantation is highly effective in real-world practice: initial results from the FMT National Registry. Gastroenterology. 2021;160(1):183-192.e3.","journal-title":"Gastroenterology"},{"key":"1030_CR18","unstructured":"Fecal Microbiota Transplantation National Registry [Internet]. American Gastroenterological Association. Available from: https:\/\/gastro.org\/research-and-awards\/registries-and-studies\/fecal-microbiota-transplantation-national-registry\/. Accessed November 1, 2025."},{"issue":"5","key":"1030_CR19","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/cid\/civ938","volume":"62","author":"R Orenstein","year":"2016","unstructured":"Orenstein R, Dubberke E, Hardi R, Ray A, Mullane K, Pardi DS, et al. Safety and durability of RBX2660 (Microbiota Suspension) for recurrent clostridium difficile infection: results of the PUNCH CD study. Clin Infect Dis. 2016;62(5):596\u2013602.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"1030_CR20","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1093\/cid\/ciy259","volume":"67","author":"ER Dubberke","year":"2018","unstructured":"Dubberke ER, Lee CH, Orenstein R, Khanna S, Hecht G, Gerding DN. Results from a Randomized, Placebo-Controlled clinical trial of a RBX2660-A Microbiota-Based drug for the prevention of recurrent clostridium difficile infection. Clin Infect Dis. 2018;67(8):1198\u2013204.","journal-title":"Clin Infect Dis"},{"issue":"15","key":"1030_CR21","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s40265-022-01797-x","volume":"82","author":"S Khanna","year":"2022","unstructured":"Khanna S, Assi M, Lee C, Yoho D, Louie T, Knapple W, et al. Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a bayesian primary analysis for the prevention of recurrent clostridioides difficile infection. Drugs. 2022;82(15):1527\u201338.","journal-title":"Drugs"},{"issue":"17","key":"1030_CR22","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1001\/jama.2014.13875","volume":"312","author":"I Youngster","year":"2014","unstructured":"Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, capsulized, frozen fecal microbiota transplantation for relapsing clostridium difficile infection. JAMA. 2014;312(17):1772\u20138.","journal-title":"JAMA"},{"issue":"6","key":"1030_CR23","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/ajg.2017.6","volume":"112","author":"C Staley","year":"2017","unstructured":"Staley C, Hamilton MJ, Vaughn BP, Graiziger CT, Newman KM, Kabage AJ, et al. Successful resolution of recurrent Clostridium difficile infection using freeze-dried, encapsulated fecal microbiota; pragmatic cohort study. Am J Gastroenterol. 2017;112(6):940\u20137.","journal-title":"Am J Gastroenterol"},{"issue":"20","key":"1030_CR24","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1001\/jama.2017.17077","volume":"318","author":"D Kao","year":"2017","unstructured":"Kao D, Roach B, Silva M, Beck P, Rioux K, Kaplan GG, et al. Effect of oral Capsule- vs Colonoscopy-Delivered fecal microbiota transplantation on recurrent clostridium difficile infection: A randomized clinical trial. JAMA. 2017;318(20):1985\u201393.","journal-title":"JAMA"},{"issue":"2","key":"1030_CR25","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1053\/j.gastro.2024.09.030","volume":"168","author":"JR Allegretti","year":"2025","unstructured":"Allegretti JR, Kelly CR, Louie T, Fischer M, Hota S, Misra B, et al. Safety and tolerability of CP101, a full-spectrum, oral microbiome therapeutic for the prevention of recurrent Clostridioides difficile infection: a phase 2 randomized controlled trial. Gastroenterology. 2025;168(2):357-366.e3.","journal-title":"Gastroenterology"},{"key":"1030_CR26","unstructured":"Portfolio, [Internet]. Finch Therapeutics. Available from: https:\/\/www.finchtherapeutics.com\/platform\/. Accessed November 1, 2025."},{"key":"1030_CR27","unstructured":"Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridioides difficile Infection Not Responsive to Standard Therapies. Guidance for Industry. November 2022. Available at https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/enforcement-policy-regarding-investigational-new-drug-requirements-use-fecal-microbiota. Accessed November 1, 2025."},{"issue":"3","key":"1030_CR28","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1053\/j.gastro.2024.01.008","volume":"166","author":"AF Peery","year":"2024","unstructured":"Peery AF, Kelly CR, Kao D, Vaughn BP, Lebwohl B, Singh S, et al. AGA clinical practice guideline on fecal microbiota\u2013based therapies for select gastrointestinal diseases. Gastroenterology. 2024;166(3):409\u201334.","journal-title":"Gastroenterology"},{"issue":"7","key":"1030_CR29","doi-asserted-by":"publisher","first-page":"940","DOI":"10.7326\/ANNALS-24-03285","volume":"178","author":"FE Juul","year":"2025","unstructured":"Juul FE, Bretthauer M, Johnsen PH, Samy F, Tonby K, Berdal JE, et al. Fecal microbiota transplantation versus vancomycin for primary Clostridioides difficile infection\u202f: a randomized controlled trial. Ann Intern Med. 2025;178(7):940\u20137.","journal-title":"Ann Intern Med"},{"issue":"3","key":"1030_CR30","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa2106516","volume":"386","author":"P Feuerstadt","year":"2022","unstructured":"Feuerstadt P, Louie TJ, Lashner B, Wang EEL, Diao L, Bryant JA, et al. SER-109, an oral Microbiome therapy for recurrent clostridioides difficile infection. N Engl J Med. 2022;386(3):220\u20139.","journal-title":"N Engl J Med"},{"key":"1030_CR31","doi-asserted-by":"crossref","unstructured":"Nguyen L, Feuerstadt P, Allegretti JR, Axelrad J. Fecal microbiota-based therapies compared to fecal microbiota transplantation for preventing recurrent C. difficile infection. Clin Gastroenterol Hepatol. 2025;S1542-3565(25)00749-9.","DOI":"10.1016\/j.cgh.2025.08.029"},{"key":"1030_CR32","unstructured":"Barlowe TS, Desai S, Sanderford AE, Holowka T, Peery AF, Mcgill SK. Fulminant clostridioides difficile infection following fecal microbiota spores compared to fecal microbiota transplant. Clin Gastroenterol Hepatol. 2025;S1542-3565(25)00420-3."},{"key":"1030_CR33","doi-asserted-by":"crossref","unstructured":"Khanna S, Feuerstadt P, Van Handel D, Blount K, Ward T, Adamowicz B. Significant and durable Microbiome restoration in a phase 3 trial of fecal Microbiota, Live-JSLM for recurrent clostridioides difficile infection when administered by Colonoscopy. Plenary session 1A at American college of gastroenterology annual scientific meeting, October 27, 2025.","DOI":"10.14309\/01.ajg.0001135652.72435.3d"},{"issue":"10","key":"1030_CR34","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/apt.15526","volume":"50","author":"EN Tixier","year":"2019","unstructured":"Tixier EN, Verheyen E, Ungaro RC, Grinspan AM. Faecal microbiota transplant decreases mortality in severe and fulminant clostridioides difficile infection in critically ill patients. Aliment Pharmacol Ther. 2019;50(10):1094\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"1030_CR35","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1093\/cid\/cix762","volume":"66","author":"M Hocquart","year":"2018","unstructured":"Hocquart M, Lagier JC, Cassir N, Saidani N, Eldin C, Kerbaj J, et al. Early fecal microbiota transplantation improves survival in severe clostridium difficile infections. Clin Infect Dis. 2018;66(5):645\u201350.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"1030_CR36","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1016\/j.cgh.2019.12.029","volume":"18","author":"YW Cheng","year":"2020","unstructured":"Cheng YW, Phelps E, Nemes S, Rogers N, Sagi S, Bohm M, et al. Fecal microbiota transplant decreases mortality in patients with refractory severe or fulminant Clostridioides difficile infection. Clin Gastroenterol Hepatol. 2020;18(10):2234-2243.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"1030_CR37","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.14309\/ajg.0000000000001278","volume":"116","author":"CR Kelly","year":"2021","unstructured":"Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, et al. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am J Gastroenterol. 2021;116(6):1124\u201347.","journal-title":"Am J Gastroenterol."},{"issue":"12","key":"1030_CR38","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S2468-1253(22)00276-X","volume":"7","author":"SMD Baunwall","year":"2022","unstructured":"Baunwall SMD, Andreasen SE, Hansen MM, Kelsen J, H\u00f8yer KL, R\u00e5g\u00e5rd N, et al. Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial. The Lancet Gastroenterology & Hepatology. 2022;7(12):1083\u201391.","journal-title":"The Lancet Gastroenterology & Hepatology"},{"issue":"12","key":"1030_CR39","doi-asserted-by":"publisher","first-page":"e0189768","DOI":"10.1371\/journal.pone.0189768","volume":"12","author":"A Camacho-Ortiz","year":"2017","unstructured":"Camacho-Ortiz A, Guti\u00e9rrez-Delgado EM, Garcia-Mazcorro JF, Mendoza-Olazar\u00e1n S, Mart\u00ednez-Mel\u00e9ndez A, Palau-Davila L, et al. Randomized clinical trial to evaluate the effect of fecal microbiota transplant for initial clostridium difficile infection in intestinal microbiome. PLoS One. 2017;12(12):e0189768.","journal-title":"PLoS One"},{"issue":"26","key":"1030_CR40","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1056\/NEJMc1803103","volume":"28","author":"FE Juul","year":"2018","unstructured":"Juul FE, Garborg K, Bretthauer M, Skudal H, \u00d8ines MN, Wiig H, et al. Fecal microbiota transplantation for primary clostridium difficile infection. N Engl J Med. 2018;28(26):2535\u20136.","journal-title":"N Engl J Med"},{"issue":"7","key":"1030_CR41","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/ajg.2014.133","volume":"109","author":"CR Kelly","year":"2014","unstructured":"Kelly CR, Ihunnah C, Fischer M, Khoruts A, Surawicz C, Afzali A, et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol. 2014;109(7):1065\u201371.","journal-title":"Am J Gastroenterol"},{"issue":"21","key":"1030_CR42","doi-asserted-by":"publisher","first-page":"6498","DOI":"10.7150\/jca.59251","volume":"12","author":"H Ali","year":"2021","unstructured":"Ali H, Khurana S, Ma W, Peng Y, Jiang ZD, DuPont H, et al. Safety and efficacy of fecal microbiota transplantation to treat and prevent recurrent Clostridioides difficile in cancer patients. J Cancer. 2021;12(21):6498\u2013506.","journal-title":"J Cancer"},{"issue":"2","key":"1030_CR43","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/ajt.15058","volume":"19","author":"YW Cheng","year":"2019","unstructured":"Cheng YW, Phelps E, Ganapini V, Khan N, Ouyang F, Xu H, et al. Fecal microbiota transplantation for the treatment of recurrent and severe Clostridium difficile infection in solid organ transplant recipients: a multicenter experience. Am J Transplant. 2019;19(2):501\u201311.","journal-title":"Am J Transplant"},{"issue":"4","key":"1030_CR44","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/tid.12550","volume":"18","author":"BJ Webb","year":"2016","unstructured":"Webb BJ, Brunner A, Ford CD, Gazdik MA, Petersen FB, Hoda D. Fecal microbiota transplantation for recurrent clostridium difficile infection in hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2016;18(4):628\u201333.","journal-title":"Transpl Infect Dis"},{"issue":"5","key":"1030_CR45","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1053\/j.gastro.2020.07.045","volume":"159","author":"JR Allegretti","year":"2020","unstructured":"Allegretti JR, Kelly CR, Grinspan A, Mullish BH, Kassam Z, Fischer M. Outcomes of fecal microbiota transplantation in patients with inflammatory bowel diseases and recurrent clostridioides difficile infection. Gastroenterology. 2020;159(5):1982\u20134.","journal-title":"Gastroenterology"},{"issue":"8630","key":"1030_CR46","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(89)91183-5","volume":"1","author":"JD Bennet","year":"1989","unstructured":"Bennet JD, Brinkman M. Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet. 1989;1(8630):164.","journal-title":"Lancet"},{"issue":"1","key":"1030_CR47","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/00004836-200307000-00012","volume":"37","author":"TJ Borody","year":"2003","unstructured":"Borody TJ, Warren EF, Leis S, Surace R, Ashman O. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol. 2003;37(1):42\u20137.","journal-title":"J Clin Gastroenterol"},{"issue":"10","key":"1030_CR48","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1038\/ajg.2013.257","volume":"108","author":"S Angelberger","year":"2013","unstructured":"Angelberger S, Reinisch W, Makristathis A, Lichtenberger C, Dejaco C, Papay P, et al. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol. 2013;108(10):1620\u201330.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"1030_CR49","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1053\/j.gastro.2015.04.001","volume":"149","author":"P Moayyedi","year":"2015","unstructured":"Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149(1):102-109.e6.","journal-title":"Gastroenterology"},{"issue":"1","key":"1030_CR50","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1053\/j.gastro.2015.03.045","volume":"149","author":"NG Rossen","year":"2015","unstructured":"Rossen NG, Fuentes S, van der Spek MJ, Tijssen JG, Hartman JHA, Duflou A, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology. 2015;149(1):110-118.e4.","journal-title":"Gastroenterology"},{"issue":"2","key":"1030_CR51","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1001\/jama.2018.20046","volume":"321","author":"SP Costello","year":"2019","unstructured":"Costello SP, Hughes PA, Waters O, Bryant RV, Vincent AD, Blatchford P, et al. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial. JAMA. 2019;321(2):156\u201364.","journal-title":"JAMA"},{"issue":"10075","key":"1030_CR52","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/S0140-6736(17)30182-4","volume":"389","author":"S Paramsothy","year":"2017","unstructured":"Paramsothy S, Kamm MA, Kaakoush NO, Walsh AJ, van den Bogaerde J, Samuel D, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017;389(10075):1218\u201328.","journal-title":"Lancet"},{"key":"1030_CR53","doi-asserted-by":"crossref","unstructured":"B\u0159ezina J, Bajer L, Wohl P, \u010euricov\u00e1 D, Hrab\u00e1k P, Novotn\u00fd A, et al. Fecal microbial transplantation versus Mesalamine enema for treatment of active left-sided ulcerative colitis-results of a randomized controlled trial. J Clin Med. 2021;22(13):2753.","DOI":"10.3390\/jcm10132753"},{"issue":"1","key":"1030_CR54","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12876-021-01856-9","volume":"21","author":"JW Crothers","year":"2021","unstructured":"Crothers JW, Chu ND, Nguyen LTT, Phillips M, Collins C, Fortner K, et al. Daily, oral FMT for long-term maintenance therapy in ulcerative colitis: results of a single-center, prospective, randomized pilot study. BMC Gastroenterol. 2021;21(1):281.","journal-title":"BMC Gastroenterol."},{"issue":"2","key":"1030_CR55","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S2468-1253(21)00400-3","volume":"7","author":"C Haifer","year":"2022","unstructured":"Haifer C, Paramsothy S, Kaakoush NO, Saikal A, Ghaly S, Yang T, et al. Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2022;7(2):141\u201351.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"1030_CR56","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.14309\/ajg.0000000000003463","volume":"3","author":"DT Rubin","year":"2025","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA, Barnes EL, Long MD. ACG clinical guideline update: ulcerative colitis in adults. Am J Gastroenterol. 2025;3(6):1187\u2013224.","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"1030_CR57","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/ibd\/izab001","volume":"27","author":"EK Karjalainen","year":"2021","unstructured":"Karjalainen EK, Renkonen-Sinisalo L, Satokari R, Mustonen H, Ristim\u00e4ki A, Arkkila P, et al. Fecal microbiota transplantation in chronic pouchitis: A Randomized, Parallel, Double-Blinded clinical trial. Inflamm Bowel Dis. 2021;27(11):1766\u201372.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"1030_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000497042","volume":"4","author":"H Herfarth","year":"2019","unstructured":"Herfarth H, Barnes EL, Long MD, Isaacs KL, Leith T, Silverstein M, et al. Combined endoscopic and oral fecal microbiota transplantation in patients with Antibiotic-Dependent pouchitis: low clinical efficacy due to low donor microbial engraftment. Inflamm Intest Dis. 2019;4(1):1\u20136.","journal-title":"Inflamm Intest Dis"},{"issue":"4","key":"1030_CR59","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1093\/ecco-jcc\/jjv203","volume":"10","author":"S Vermeire","year":"2016","unstructured":"Vermeire S, Joossens M, Verbeke K, Wang J, Machiels K, Sabino J, et al. Donor species richness determines faecal microbiota transplantation success in inflammatory bowel disease. J Crohns Colitis. 2016;10(4):387\u201394.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"1030_CR60","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40168-020-0792-5","volume":"8","author":"H Sokol","year":"2020","unstructured":"Sokol H, Landman C, Seksik P, Berard L, Montil M, Nion-Larmurier I, et al. Fecal microbiota transplantation to maintain remission in crohn\u2019s disease: a pilot randomized controlled study. Microbiome. 2020;8(1):12.","journal-title":"Microbiome"},{"issue":"6","key":"1030_CR61","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.14309\/ajg.0000000000003196","volume":"120","author":"D Kao","year":"2024","unstructured":"Kao D, Wong K, Jijon H, Moayyedi P, Franz R, McDougall C, et al. Preliminary results from a Multicenter, randomized trial using fecal microbiota transplantation to induce remission in patients with Mild-to-Moderate crohn\u2019s disease. Am J Gastroenterol. 2024;120(6):1334\u201344.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"1030_CR62","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.14309\/ajg.0000000000003465","volume":"3","author":"GR Lichtenstein","year":"2025","unstructured":"Lichtenstein GR, Loftus EV, Afzali A, Long MD, Barnes EL, Isaacs KL, et al. ACG clinical guideline: management of crohn\u2019s disease in adults. Am J Gastroenterol. 2025;3(6):1225\u201364.","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"1030_CR63","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1038\/ajg.2014.295","volume":"109","author":"DM Pinn","year":"2014","unstructured":"Pinn DM, Aroniadis OC, Brandt LJ. Is fecal microbiota transplantation the answer for irritable bowel syndrome? A single-center experience. Am J Gastroenterol. 2014;109(11):1831\u20132.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"1030_CR64","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(17)30338-2","volume":"3","author":"PH Johnsen","year":"2018","unstructured":"Johnsen PH, Hilp\u00fcsch F, Cavanagh JP, Leikanger IS, Kolstad C, Valle PC, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol. 2018;3(1):17\u201324.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"1030_CR65","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/00365521.2021.1915375","volume":"56","author":"AMA Madsen","year":"2021","unstructured":"Madsen AMA, Halkj\u00e6r SI, Christensen AH, G\u00fcnther S, Browne PD, Kallemose T, et al. The effect of faecal microbiota transplantation on abdominal pain, stool frequency, and stool form in patients with moderate-to-severe irritable bowel syndrome: results from a randomised, double-blind, placebo-controlled study. Scand J Gastroenterol. 2021;56(7):761\u20139.","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"1030_CR66","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/gutjnl-2019-319630","volume":"69","author":"M El-Salhy","year":"2020","unstructured":"El-Salhy M, Hatlebakk JG, Gilja OH, Br\u00e5then Kristoffersen A, Hausken T. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut. 2020;69(5):859\u201367.","journal-title":"Gut"},{"key":"1030_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.994911","volume":"9","author":"S Tkach","year":"2022","unstructured":"Tkach S, Dorofeyev A, Kuzenko I, Sulaieva O, Falalyeyeva T, Kobyliak N. Fecal microbiota transplantation in patients with post-infectious irritable bowel syndrome: a randomized, clinical trial. Front Med (Lausanne). 2022;9:994911.","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"1030_CR68","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1136\/gutjnl-2018-316434","volume":"67","author":"SI Halkj\u00e6r","year":"2018","unstructured":"Halkj\u00e6r SI, Christensen AH, Lo BZS, Browne PD, G\u00fcnther S, Hansen LH, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut. 2018;67(12):2107\u201315.","journal-title":"Gut"},{"issue":"9","key":"1030_CR69","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S2468-1253(19)30198-0","volume":"4","author":"OC Aroniadis","year":"2019","unstructured":"Aroniadis OC, Brandt LJ, Oneto C, Feuerstadt P, Sherman A, Wolkoff AW, et al. Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2019;4(9):675\u201385.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"1030_CR70","doi-asserted-by":"publisher","first-page":"e00034","DOI":"10.14309\/ctg.0000000000000034","volume":"10","author":"S Holster","year":"2019","unstructured":"Holster S, Lindqvist CM, Repsilber D, Salonen A, de Vos WM, K\u00f6nig J, et al. The effect of allogenic versus autologous fecal microbiota transfer on Symptoms, visceral perception and fecal and mucosal microbiota in irritable bowel syndrome: a randomized controlled study. Clin Transl Gastroenterol. 2019;10(4):e00034.","journal-title":"Clin Transl Gastroenterol"},{"issue":"12","key":"1030_CR71","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1111\/apt.15740","volume":"51","author":"P Lahtinen","year":"2020","unstructured":"Lahtinen P, Jalanka J, Hartikainen A, Mattila E, Hillil\u00e4 M, Punkkinen J, et al. Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome. Aliment Pharmacol Ther. 2020;51(12):1321\u201331.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1030_CR72","doi-asserted-by":"publisher","first-page":"17","DOI":"10.14309\/ajg.0000000000001036","volume":"116","author":"BE Lacy","year":"2021","unstructured":"Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, et al. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol. 2021;116(1):17\u201344.","journal-title":"Am J Gastroenterol"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-025-01030-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11894-025-01030-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-025-01030-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T04:57:19Z","timestamp":1768366639000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11894-025-01030-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1030"],"URL":"https:\/\/doi.org\/10.1007\/s11894-025-01030-1","relation":{},"ISSN":["1534-312X"],"issn-type":[{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"3 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The views expressed are those of the author(s) and do not necessarily reflect the official policy or position of the Defense Health Agency, the Department of Defense, nor any agencies under the U.S. Government.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}